CSIMarket
 
Nuo Therapeutics, Inc.  (CMXI)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 124
 Employees -
 Revenues (TTM) (Millions $) 9
 Net Income (TTM) (Millions $) -27
 Cash Flow (TTM) (Millions $) 15
 Capital Exp. (TTM) (Millions $) 0

Nuo Therapeutics, Inc.
Nuo Therapeutics, Inc. was a biopharmaceutical company that focused on developing and commercializing advanced wound care products. The company aimed to provide innovative solutions for the treatment of chronic and acute wounds, including diabetic foot ulcers.

Nuo Therapeutics developed a proprietary platform technology called Aurix, which utilized the patient's own blood to create a platelet and plasma-based therapy. This therapy was designed to promote wound healing and reduce inflammation, offering a potential alternative to traditional wound care approaches.

However, it is worth noting that as of my last knowledge update in 2021, Nuo Therapeutics, Inc. is no longer in operation. The company filed for bankruptcy and its assets were acquired by MiMedx Group, Inc. in 201


   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Omniab Inc

OABI Suffers Massive Losses, Revenue Plummets by 91.838% in Fiscal Period Ending December 31, 2023

OmniAb, Inc. recently announced its financial results for the most recent fiscal period, and the numbers are quite alarming. The company experienced a significant decline in revenue, with a staggering decrease of -91.838% to $4.82 million. This is a worrisome trend, especially considering that revenue had already fallen by -11.959% in the preceding reporting period.
Additionally, the company's shortfall per share has extended to $-0.08, compared to $-0.16 from the corresponding reporting period a year prior. This represents a decline in profitability, which could be a cause for concern among investors. The net shortfall for the fiscal period ending December 31, 2023, was reported as $-14.053 million, surpassing the $-13.881 million from the previous year.

Absci Corp

Absci Corp Takes a Financial Hit: Revenue Plummets by 78% in Fourth Quarter

Investors Beware: ABSI Reports Disastrous Fourth Quarter of 2023 Financial Results
Absci Corp (Nasdaq: ABSI) recently released its fourth quarter of 2023 financial report, and the numbers are painting a bleak picture for the company. Revenue took a nosedive, fading by a staggering -78.292% to just $0.34 million, while the net loss per share swelled to $-0.25, compared to $-0.24 in the previous reporting season. Additionally, revenue tumbled sequentially by -54.57% from the preceding quarter, dropping from $0.74 million.
The fourth quarter of 2023 earnings season saw Absci Corp realize a net loss of $-23.545 million, a significant increase from $-19.471 million in the same period a year ago. The company also experienced a buildup in accounts receivable, signaling rising demand, with accounts receivables valued at $2.2 million, higher than in the preceding quarter.

Sera Prognostics Inc

Despite Stock Growth, Sera Prognostics Inc Faces Financial Challenges in Latest Fiscal Period



Sera Prognostics Inc, a renowned medical laboratory specializing in improving maternal and neonatal health through innovative pregnancy biomarker information, recently announced its financial results for the fourth quarter of 2023. While the company's stock underwent a slight drop over the last five trading days, it still reflects an impressive 83.94% increase over the past 90 days. Additionally, Sera Prognostics Inc's stock is currently trading on NASDAQ, exhibiting a significant 129.7% value above its 52-week average.
Financial Results:
Sera Prognostics Inc's financial report for the fiscal period ending December 31, 2023, revealed several challenges. The company experienced a staggering 36.923% decline in revenue to $0.04 million and recorded a shortfall per share of $-0.25 compared to $-0.26 in the previous year. This indicates a persistent decrease in revenue and profitability, highlighting the need for strategic changes.

Exagen Inc

Evanescence of Deficit: XGN Struggles with Weakness in Fourth Quarter Financial Report

Exagen Inc (Nasdaq: XGN) has shown significant signs of weakness in its latest financial report for the fourth quarter of 2023. Despite a decrease in the loss per share compared to the previous year, the company still reported a loss of $-0.30 per share. This is only a slight improvement from the loss of $-0.83 per share in the same period a year prior.
Although there was a 7.229% increase in revenue to $13.77 million from $12.84 million in the corresponding reporting season, this is a relatively small growth rate and not enough to inspire confidence in the company's prospects. The sequential revenue growth of 2.601% from $13.42 million is also modest at best.

Enzo Biochem Inc

Enzo Biochem Inc Revenue Plummeted during November to January 31, 2024 Period

Enzo Biochem Inc, a medical laboratories company, experienced a stable stock performance in March 2024 with no change in its share price. However, this brings the share price to a decrease of 11.33% in the first quarter of 2024. Additionally, the stock is currently trading only 33% above its 52-week low.
For the financial second quarter of 2024, Enzo Biochem Inc reported a significant improvement in its earnings per share (EPS) compared to the previous year. The loss per share decreased from $-0.23 to $-0.06. Furthermore, the EPS also improved from the preceding quarter, going from $-0.13 to $-0.06.






 

Nuo Therapeutics's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com